Radiation therapy in cervical carcinoma fifteen years experience in a Norwegian health region

Background: To study the treatment of patients with cervical carcinoma with regard to side effects and survival. Materials and Methods: A retrospective analysis of 107 patients with cervical carcinoma treated by radiotherapy with curative intent between January 1, 1987 and December 31, 2001. Results: Median follow-up: 139 months for surviving patients and 23 months for deceased patients. Five-year overall and disease-specific survival for all stages was 36% and 45%, respectively. Corresponding figures for each stage were, Stage I: 54% and 80%, Stage II: 41% and 56% Stage III: 33% and 36% and Stage IV: < 1%. Five-year actuarial incidence of late reactions, all grades were: vagina 77%, rectum 41%, urinary tract 28%. and gastrointestinal tract 37%. Interpretation: a great variation of treatment techniques resulted in an overall survival somewhat interior to that in other comparable series. Over time, an increasing tendency to include brachytherapy and external tumour boost was observed.

Cervical carcinoma; Radiation therapy; Late reactions; Survival.

[1] Sundfor K., Tropé C.G., Hogberg T., Onsrud M., Koern J., Simonsen E. et al.: "Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma". Cancer, 1996, 77, 2371.

[2] ICRU Report 38: "Dose and volume specification for reporting intracavitary therapy in gynecology". Bethesda, MD: International Commission on Radiation Units and Measurements, 1985.

[3] Lindegaard J.C., Mirza M.R., Lorenz E., Lundqvist E.A.: "A Nordic feasibility study of accelerated radiotherapy and concomitant cisplatin in the treatment of advanced cervical cancer stageIIB – IVA (NSGO-CC-9901)". Radiother. Oncol. , 2002, 64 (suppl.1), 49.

[4] Cox J.D., Stetz J., Pajak T.F: "Toxicity Criteria Of The Radiation Therapy Oncology Group (RTOG) And The European Organization For Research And Treatment Of Cancer (EORTC)". Int. J.Radiat. Oncol. Biol. Phys. , 1995, 31, 1341.

[5] The Revised Common Toxicity Criteria: Version 2.0 CTEP website http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf.

[6] Fowler J.F: "The linear-quadratic formula and progress in fractionated radiotherapy". Br. J. Radiol. , 1989, 62, 679.

[7] Joiner M.C., van der Kogel A.J.: "The linear quadratic approach to fractionation and calculation of isoeffect relationships". In: SteelG.G. (ed.) Basic Clinical Radiobiology. 20 edition, London, Arnold, 1997, 106.

[8] Bent S., Padula A., Avins A.L.: "Brief communication: better ways to question patients about adverse medical events". Ann. Intern.Med. , 2006, 144, 257.

[9] Wang C.J., Leung S.W., Chen H.C., Sun L.M., Fang F.M., Changchien C.C. et al.: "High-dose rate intracavitary brachytherapy (HDR-IC)". In: "Treatment of Cervical Carcinoma: 5-year Results and Implication of Increased Low-Grade Rectal Complication on Initiation of an HDR-IC Fractionation Scheme". Int. J.Radiat. Oncol. Biol. Phys. , 1997, 38, 391.

[10] Pötter R., Knocke T.H., Fer C., Baldass M., Reinthaller A., KuceraH. : " Definitive radiotherapy based on HDR brachytherapy with ridium n uterine cervix carcinoma: report on the Vienna University Hospital findings (1993-1997) compared to the preceding period in the context of ICRU 38 recommendations". CancerRadiother, 2000, 4, 159.

[11] Yamashita H., Nakagawa K., Tago M., Shiraishi K., Nakamura N., Ohtomo K.: "Treatment results and prognostic analysis of radical radiotherapy for locally advanced cancer of the uterine cervix". BrJ. Radiol. , 2005, 78, 821.

[12] Pötter R., Dimopoulos J., Georg P., Lang S., Waldhäusl C.,Wachter-Gerstner N. et al.: "Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer". Radiother. Oncol. , 2007, 83, 148.

[13] Logsdon M.D., Eifel P.J.: "FIGO IIIB Squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy". Int. J. Radiat. Oncol. Biol. Phys. , 1999, 43, 763.

[14] "LENT SOMA scales for all anatomic sites". Int. J. Radiat. Oncol. Biol. Phys. , 1995, 31, 1049.

[15] Trotti A., Byhardt R., Stetz J., Gwede C., Corn B., Fu K. et al.:d"Common toxicity criteria: Version 2.0 an improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy". Int. J. Radiat. Oncol. Biol. Phys. , 2000, 47, 13.

[16] Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V. et al.: "CTCAE v3.0: development of a comprehensive grading. system for the adverse effects of cancer treatment". Semin. Radiat.Oncol. , 2003, 13, 176.

[17] Hanlon A.L., Schultheiss T.E., Hunt M.A., Movsas B., Peder R.S., Hanks G.E.: "Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales". Int. J. Radiat. Oncol. Biol. Phys. , 1997, 38, 59.

[18] Boersma L.J., van den Brink M., Bruce A.M., Shouman T., GrasL. , Velde A. et al.: "Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms". Int. J. Radiat. Oncol. Biol. Phys. , 1998, 41, 83.

[19] Trotti A., Bentzen S.M.: "The need for adverse effects reporting standards in Oncology clinical trials". J. Clin. Oncol. , 2004, 22, 19.

[20] Bentzen S.M., Vaeth M., Pedersen D.E., Overgaard J.: "Why actuarial estimates should be used in reporting late normal-tissue effects of cancer treatment". Int. J. Radiat. Oncol. Biol. Phys. ,1995, 32, 1531.

[21] Bentzen S.M., Dorr W., Anscher M.S., Denham J.W., Hauer-JensenM. , Marks L.B., Williams J.: "Normal tissue effects: Reporting andanalysis". Semin. Radiat. Oncol. , 2003 13, 189.

[22] Bentzen S.M., Trotti A.: "Evaluation of early and late toxicities in chemoradiation trials". J. Clin. Oncol. , 2007, 25, 4096.

[23] Dimopoulos J., Petrow P.: "Contouring of GTV, CTV and OAR. CT and MR Imaging, GYN GEC ESTRO Recommendations".Radiother. Oncol. , 2007, 83 (suppl. 1), 7.

[24] Viswanathan A.K., Dimopouos J., Kirisits C., Berger D., Pötter R.: "Computed tomography versus magnetic resonance imagingbased contouring in cervical cancer brachytherapy: resulsts of a prospektive trial and preliminary guidelines for standardized contours". Int. J. Radiat. Oncol. Biol. Phys. , 2007, 68, 491.

[25] Haie-Meder C., Pötter R., van Limbergen E., Briot E., De Brabandere M., Dimopoulos J. et al.: "Recommendations from gynaecological (GYN) GEC-ESTRO working group: concepts and terms in 3D image-based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV andCTV". Radiother. Oncol. , 2005, 74, 235.

[26] Pötter R., Haie-Meder C., van Limbergen E., Barillot I., De Brabandere M., Dimopoulos J. et al.: "Recommendations from gynaecological (GYN) GEC-ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology". Radiother.Oncol. , 2006, 78, 67.

[27] Portelance L., Chao C., Grigsby P.W., Bennet H., Low D.: "Intensity-Modulated Radiation Therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation". Int. J. Radiat. Oncol. Biol. Phys. , 2001, 51, 261.

[28] Roeske J.C., Bonta D., Mell L.K., Lujan A.E., Mundt A.J.: "A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy". Radiother Oncol. , 2003, 69, 201.

[29] Mundt A.J., Lujan A.E., Rotmensch J., Waggoner S.E., Yamada S.D., Fleming G. et al.: "Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies". Int. J. Radiat. Oncol. Biol. Phys. , 2002, 52, 1330.